KROS (NASDAQ) - Keros Therapeutics Inc | Stock Price & Analysis

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4923271013
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for KROS (NASDAQ) - Keros Therapeutics Inc | Stock Price & Analysis


Market Cap in USD 907m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-04-08


Fundamental -
Dividend -
Performance 5y 0.47
Rel. Performance vs Sector -2.92
Analysts 4.78
Fair Price Total Ret. 26.95
Fair Price DCF todo


Growth TTM -39.43%
CAGR 5y 11.93%
CAGR / Mean Drawdown 0.31
Sharpe Ratio TTM -0.90
Alpha vs SP500 TTM -57.89
Beta vs SP500 5y weekly 1.54
CAPM 9.52%
Average Daily Range 2m 5.34%
Reversal Oscillator 55.32
Volatility GJR Garch 1y 62.30%
Price / SMA 50 0.46%
Price / SMA 200 -23.25%
Current Volume 295.9k
Average Volume 20d 280k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%